Keyword: Unum Therapeutics
Unum suffered the setback after a patient experienced grade 3 and 4 adverse events including neurotoxicity and respiratory distress.
The total falls short of the amount Unum set out to raise but leaves it with enough cash to advance two cell therapies in four clinical trials.
Jamie Macdonald succeeds Joseph von Rickenbach as Parexel CEO, Roche promotes William Pao to replace John Reed as pRED head, Moderna loses vaccines head.
Unum revealed more than its IPO goals in its SEC filing: a clinical hold and two patient deaths.